NVO vs. BOC
NVO (Novo Nordisk A/S) and BOC (Boston Omaha Corp) are both stocks. NVO operates in Drug Manufacturers - General (Healthcare), while BOC operates in Advertising Agencies (Communication Services). Over the past 5 years, NVO returned 2.92%/yr vs -16.42%/yr for BOC. At a 0.10 correlation, their price movements are largely independent.
Performance
NVO vs. BOC - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVO achieves a -10.74% return, which is significantly lower than BOC's 10.02% return.
NVO
- 1D
- -0.18%
- 1M
- -6.80%
- YTD
- -10.74%
- 6M
- -9.50%
- 1Y
- -43.34%
- 3Y*
- -15.59%
- 5Y*
- 2.92%
- 10Y*
- 7.56%
BOC
- 1D
- 1.80%
- 1M
- 21.30%
- YTD
- 10.02%
- 6M
- 0.52%
- 1Y
- -2.58%
- 3Y*
- -11.81%
- 5Y*
- -16.42%
- 10Y*
- —
NVO vs. BOC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | -10.74% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 26.93% |
BOC Boston Omaha Corp | 10.02% | -12.76% | -9.85% | -40.64% | -7.76% | 3.91% | 31.42% | -10.09% | -27.76% | 149.15% |
Correlation
The correlation between NVO and BOC is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.06 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since Jun 16, 2017 | 0.10 |
The correlation between NVO and BOC shifts across timeframes, from 0.06 (3 years) to 0.18 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
NVO:
$195.21B
BOC:
$419.25M
NVO:
DKK 27.42
BOC:
-$0.44
NVO:
3.85
BOC:
3.71
NVO:
6.21
BOC:
0.82
NVO:
DKK 327.80B
BOC:
$114.89M
NVO:
DKK 268.30B
BOC:
$105.55M
NVO:
DKK 181.54B
BOC:
$2.48M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVO vs. BOC — Risk / Return Rank
NVO
BOC
NVO vs. BOC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Boston Omaha Corp (BOC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVO | BOC | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.76 | ||
| Sortino ratioReturn per unit of downside risk | -1.17 | ||
| Omega ratioGain probability vs. loss probability | 0.85 | 1.02 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | -0.80 | -0.11 | -0.69 |
| Martin ratioReturn relative to average drawdown | -1.18 | -0.22 | -0.96 |
Loading charts...
Drawdowns
NVO vs. BOC - Drawdown Comparison
The maximum NVO drawdown since its inception was -74.70%, roughly equal to the maximum BOC drawdown of -76.58%. Use the drawdown chart below to compare losses from any high point for NVO and BOC.
Loading charts...
Drawdown Indicators
| NVO | BOC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.70% | -76.58% | +1.88% |
Max Drawdown (1Y)Largest decline over 1 year | -54.34% | -23.46% | -30.88% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | -44.53% | -30.17% |
Max Drawdown (5Y)Largest decline over 5 years | -74.70% | -74.13% | -0.57% |
Max Drawdown (10Y)Largest decline over 10 years | -74.70% | — | — |
Current DrawdownCurrent decline from peak | -68.11% | -71.18% | +3.07% |
Average DrawdownAverage peak-to-trough decline | -17.79% | -46.11% | +28.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.62% | 11.87% | +25.75% |
Volatility
NVO vs. BOC - Volatility Comparison
The current volatility for Novo Nordisk A/S (NVO) is 10.68%, while Boston Omaha Corp (BOC) has a volatility of 15.59%. This indicates that NVO experiences smaller price fluctuations and is considered to be less risky than BOC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVO | BOC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.68% | 15.59% | -4.91% |
Volatility (6M)Calculated over the trailing 6-month period | 38.04% | 22.81% | +15.23% |
Volatility (1Y)Calculated over the trailing 1-year period | 51.88% | 32.33% | +19.55% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.33% | 35.20% | +3.13% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.56% | 42.82% | -10.26% |
Dividends
NVO vs. BOC - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 4.11%, while BOC has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BOC Boston Omaha Corp | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 4.11% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
NVO vs. BOC - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Boston Omaha Corp. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVO vs. BOC - Profitability Comparison
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
BOC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Boston Omaha Corp reported a gross profit of 24.76M and revenue of 28.25M. Therefore, the gross margin over that period was 87.7%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
BOC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Boston Omaha Corp reported an operating income of -2.19M and revenue of 28.25M, resulting in an operating margin of -7.8%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
BOC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Boston Omaha Corp reported a net income of -2.15M and revenue of 28.25M, resulting in a net margin of -7.6%.
Frequently Asked Questions
NVO and BOC have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BOC has higher volatility (15.59%) compared to NVO (10.68%). In terms of maximum drawdown, NVO dropped -74.70% vs BOC's -76.58%.
BOC currently has the higher Sharpe Ratio (-0.08 vs -0.84), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVO and BOC
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer